S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Adaptimmune Therapeutics Stock Forecast, Price & News

-0.05 (-1.63%)
(As of 01/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.19 million shs
Average Volume
678,482 shs
Market Capitalization
$470.17 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Adaptimmune Therapeutics logo

About Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.


Adaptimmune Therapeutics (NASDAQ:ADAP) Sees Large Volume Increase
January 13, 2022 |  americanbankingnews.com
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $4.11
December 28, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3.96 million
Book Value
$2.20 per share


Net Income
$-130.09 million
Net Margins
Pretax Margin




Free Float
Market Cap
$470.17 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.12 out of 5 stars

Medical Sector

495th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

77th out of 206 stocks

Analyst Opinion: 3.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

Is Adaptimmune Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Adaptimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View analyst ratings for Adaptimmune Therapeutics
or view top-rated stocks.

How has Adaptimmune Therapeutics' stock been impacted by Coronavirus?

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADAP stock has increased by 2.4% and is now trading at $3.01.
View which stocks have been most impacted by COVID-19

Are investors shorting Adaptimmune Therapeutics?

Adaptimmune Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totaling 4,840,000 shares, an increase of 29.4% from the December 15th total of 3,740,000 shares. Based on an average daily trading volume, of 832,100 shares, the short-interest ratio is currently 5.8 days. Approximately 3.5% of the company's shares are short sold.
View Adaptimmune Therapeutics' Short Interest

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Adaptimmune Therapeutics

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biotechnology company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.20 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 53.31% and a negative net margin of 2,499.92%. During the same period in the previous year, the business earned ($0.23) EPS.
View Adaptimmune Therapeutics' earnings history

What price target have analysts set for ADAP?

5 brokerages have issued 1 year target prices for Adaptimmune Therapeutics' shares. Their forecasts range from $4.00 to $15.00. On average, they expect Adaptimmune Therapeutics' share price to reach $8.40 in the next twelve months. This suggests a possible upside of 179.1% from the stock's current price.
View analysts' price targets for Adaptimmune Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the following people:
  • Adrian Rawcliffe, Chief Executive Officer & Director (LinkedIn Profile)
  • William C. Bertrand, Chief Operating Officer
  • Gavin Wood, Chief Financial Officer
  • Elliot Norry, Chief Medical Officer
  • Helena Katrina Tayton-Martin, Chief Business Officer

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics CEO Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among Adaptimmune Therapeutics' employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $3.01.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics has a market capitalization of $470.17 million and generates $3.96 million in revenue each year. The biotechnology company earns $-130.09 million in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

Adaptimmune Therapeutics employs 2,020 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

Where are Adaptimmune Therapeutics' headquarters?

Adaptimmune Therapeutics is headquartered at 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 441235430000, via email at [email protected], or via fax at 44-12-3543-0001.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.